Vaccine Business is Very, Very Good for #Pharma, Especially Pfizer! | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Pfizer has reported a hefty increase in sales of its Prevnar family of pneumonia vaccines, prompting medical charities to call for a price cut.


Prevnar sales rose 43% in the fourth-quarter to $1.86bn, taking the revenues for the product in 2015 as a whole to $6.25bn as group's annual revenues dipped 25 to $48.85bn thanks largely to the strong dollar.


Medecins sans Frontieres (MSF) responded to the results announcement with an immediate call for Pfizer to reduce the price of Prevnar, saying the pneumonia vaccine "accounts for 45% of the total cost to vaccinate a child today in the poorest countries".

"Yet again, Pfizer is reporting sky-high global sales, bolstered in large part by the blockbuster pneumonia vaccine, which the company continues to price out of reach for millions of children in developing countries," said MSF Access Campaign executive director Manica Balasegaram.


The company's global vaccine revenue rose 45% to $1.92bn in the fourth quarter, with a heft chunk of the Prevnar increase coming from a doubling of sales in the US. Group revenues met expectations with a 7% rise to $14.05bn.